Entrada Therapeutics Reports 95% Decline in Collaboration Revenue and Increased Net Losses in Q1 2026

Entrada Therapeutics, Inc. reported its financial results for the first quarter of 2026, revealing a significant decline in collaboration revenue and an increase in net losses compared to the same period in 2025. The company generated $875,000 in collaboration revenue, a decrease of approximately 95% from $20.6 million in the first quarter of 2025. This decline is attributed to the completion of research activities related to its collaboration with Vertex Pharmaceuticals for the VX-670 therapeutic candidate. Operating expenses for the quarter totaled $43.2 million, slightly up from $42.3 million year-over-year, with research and development expenses increasing to $33.1 million from $32.1 million.

The net loss for the quarter was $39.7 million, compared to a loss of $17.3 million in the prior year, reflecting a year-over-year increase of 129%. The loss per share also widened to $0.95 from $0.42. The increase in losses is primarily due to the reduced collaboration revenue and ongoing investments in research and development, particularly in the company's Duchenne muscular dystrophy (DMD) programs. The company reported cash, cash equivalents, and marketable securities of $254.9 million as of March 31, 2026, which it believes will be sufficient to fund operations into the third quarter of 2027.

In terms of operational developments, Entrada continues to advance its clinical programs, particularly in DMD, with four ongoing clinical-stage programs. The company has completed the first cohort of its ENTR-601-44 clinical trial, which demonstrated favorable safety and tolerability, and is now transitioning to the open-label portion of the study. Additionally, the company is preparing for the initiation of further cohorts and expects to report additional data from these trials throughout 2026. The partnership with Vertex Pharmaceuticals remains a key strategic focus, with Vertex expected to share results from the VX-670 study in the second half of 2026.

Entrada's employee headcount has remained stable, and the company continues to invest in its research and development capabilities. The company is also exploring opportunities to expand its preclinical pipeline, particularly in ocular programs aimed at treating inherited retinal diseases. Despite the challenges faced in the current fiscal period, Entrada remains committed to its long-term strategy of developing innovative therapies for unmet medical needs.

Looking ahead, Entrada anticipates that its research and development expenses will continue to rise as it advances its clinical trials and prepares for potential commercialization of its therapeutic candidates. The company acknowledges the need for additional financing to support its operations and growth strategy, which may include equity offerings, collaborations, or other financing arrangements. The management remains optimistic about the potential of its therapeutic candidates and the impact they could have on patients' lives, while also recognizing the inherent risks and uncertainties in the biotechnology sector.